• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail

  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  12/28/2001
 
Trade Name:  Rebetron; Rebetrol
 
Generic Name or Proper Name (*):  ribavirin/intron a; ribavirin
 
Indications Studied:  Chronic hepatitis C
 
Label Changes Summary:  * Labeling for 3 years to 16 years * There are no safety and efficacy data on treatment for longer than 48 weeks in pediatric patients * Pharmacokinetic information on patients 5 to 16 years with chronic hepatitis C virus infection * Increased incidence of suicidal ideation or attempts (2.4% versus 1%) among pediatric patients compared to adult patients * Decrease in rate of linear growth (mean percentile assignment decrease of 9%) and in rate of weight gain (mean percentile assignment decrease of 13%) during 48 weeks of treatment; a general reversal was noted during the 24 week post treatment period * Patients with viral genotype 1, had a lower response rate to combination therapy compared to patients with genotype non-1, 36% versus 81% * In general, the adverse event profile in the pediatric population was similar to that observed in adults * New oral suspension developed
 
Product Labeling:  Labeling  Opens a new window
 
BPCA(B):  B
 
Sponsor:  Schering
 
Pediatric Exclusivity Granted Date:  05/09/2001
 
NNPS:  FALSE
 
Therapeutic Category:  Antiviral
 
-
-